D
Altimmune, Inc.
ALT
$5.61
-$0.36-6.03%
D
Sell
12/2/2024Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 12/2/2024 due to an increase in the volatility index and total return index.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 12/2/2024 due to an increase in the volatility index and total return index.
E
Sell
11/15/2024Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 11/15/2024 due to a decline in the valuation index and volatility index.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 11/15/2024 due to a decline in the valuation index and volatility index.
D
Sell
12/6/2023Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 12/6/2023 due to an increase in the volatility index and total return index.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 12/6/2023 due to an increase in the volatility index and total return index.
E
Sell
8/29/2023Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 8/29/2023 due to a decline in the solvency index, volatility index and total return index.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 8/29/2023 due to a decline in the solvency index, volatility index and total return index.
D
Sell
8/11/2023Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 8/11/2023 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.4005 to -$0.3168, EBIT increased 17.24% from -$21.76M to -$18.01M, and operating cash flow increased 0.12% from -$19.41M to -$19.38M.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 8/11/2023 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.4005 to -$0.3168, EBIT increased 17.24% from -$21.76M to -$18.01M, and operating cash flow increased 0.12% from -$19.41M to -$19.38M.
E
Sell
5/19/2023Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 5/19/2023 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 12.14% from -$17.31M to -$19.41M.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 5/19/2023 due to a decline in the volatility index, total return index and growth index. Operating cash flow declined 12.14% from -$17.31M to -$19.41M.
D
Sell
5/10/2023Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 5/10/2023 due to an increase in the volatility index.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 5/10/2023 due to an increase in the volatility index.
E
Sell
4/20/2023Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 4/20/2023 due to a major decline in the total return index and volatility index.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 4/20/2023 due to a major decline in the total return index and volatility index.
D
Sell
3/14/2023Downgrade
Altimmune, Inc. (ALT) was downgraded to D- from D+ on 3/14/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 13.1 to 10.99.
Altimmune, Inc. (ALT) was downgraded to D- from D+ on 3/14/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 13.1 to 10.99.
D
Sell
2/17/2023Upgraded
Altimmune, Inc. (ALT) was upgraded to D+ from D- on 2/17/2023 due to an increase in the valuation index.
Altimmune, Inc. (ALT) was upgraded to D+ from D- on 2/17/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Altimmune, Inc. (ALT) was downgraded to D- from D on 2/8/2023 due to a large decline in the total return index and valuation index.
Altimmune, Inc. (ALT) was downgraded to D- from D on 2/8/2023 due to a large decline in the total return index and valuation index.
D
Sell
11/15/2022Downgrade
Altimmune, Inc. (ALT) was downgraded to D from D+ on 11/15/2022 due to a decline in the valuation index.
Altimmune, Inc. (ALT) was downgraded to D from D+ on 11/15/2022 due to a decline in the valuation index.
D
Sell
10/21/2022Upgraded
Altimmune, Inc. (ALT) was upgraded to D+ from D on 10/21/2022 due to a substantial increase in the total return index, solvency index and volatility index. The quick ratio increased from 9.73 to 13.78.
Altimmune, Inc. (ALT) was upgraded to D+ from D on 10/21/2022 due to a substantial increase in the total return index, solvency index and volatility index. The quick ratio increased from 9.73 to 13.78.
D
Sell
5/31/2022Upgraded
Altimmune, Inc. (ALT) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index and total return index.
Altimmune, Inc. (ALT) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index and total return index.
D
Sell
5/13/2022Downgrade
Altimmune, Inc. (ALT) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and total return index. Total revenue declined 99.02% from $3.28M to $32, and the quick ratio declined from 10.73 to 9.73.
Altimmune, Inc. (ALT) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index, solvency index and total return index. Total revenue declined 99.02% from $3.28M to $32, and the quick ratio declined from 10.73 to 9.73.
D
Sell
5/5/2022Upgraded
Altimmune, Inc. (ALT) was upgraded to D from D- on 05/05/2022.
Altimmune, Inc. (ALT) was upgraded to D from D- on 05/05/2022.
D
Sell
4/20/2022Downgrade
Altimmune, Inc. (ALT) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and volatility index.
Altimmune, Inc. (ALT) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/10/2021Upgraded
Altimmune, Inc. (ALT) was upgraded to D from D- on 11/10/2021 due to an increase in the total return index and valuation index.
Altimmune, Inc. (ALT) was upgraded to D from D- on 11/10/2021 due to an increase in the total return index and valuation index.
D
Sell
11/8/2021Downgrade
Altimmune, Inc. (ALT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index and valuation index. Total revenue declined 83.57% from $837.5 to $137.6, earnings per share declined from -$0.382 to -$0.6003, and EBIT declined 20.11% from -$13.98M to -$16.79M.
Altimmune, Inc. (ALT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index and valuation index. Total revenue declined 83.57% from $837.5 to $137.6, earnings per share declined from -$0.382 to -$0.6003, and EBIT declined 20.11% from -$13.98M to -$16.79M.
D
Sell
5/1/2020Upgraded
Altimmune, Inc. (ALT) was upgraded to D from D- on 5/1/2020 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.7407 to -$0.2721, EBIT increased 57.77% from -$10.21M to -$4.31M, and operating cash flow increased 17.5% from -$2.43M to -$2M.
Altimmune, Inc. (ALT) was upgraded to D from D- on 5/1/2020 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.7407 to -$0.2721, EBIT increased 57.77% from -$10.21M to -$4.31M, and operating cash flow increased 17.5% from -$2.43M to -$2M.
D
Sell
1/2/2020Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 1/2/2020 due to an increase in the total return index and volatility index.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 1/2/2020 due to an increase in the total return index and volatility index.
E
Sell
11/15/2019Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 11/15/2019 due to a large decline in the growth index, solvency index and valuation index. EBIT declined 248.23% from -$2.93M to -$10.21M, earnings per share declined from -$0.258 to -$0.7407, and total revenue declined 60.39% from $1.63M to $644.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 11/15/2019 due to a large decline in the growth index, solvency index and valuation index. EBIT declined 248.23% from -$2.93M to -$10.21M, earnings per share declined from -$0.258 to -$0.7407, and total revenue declined 60.39% from $1.63M to $644.
D
Sell
10/3/2019Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 10/3/2019 due to an increase in the volatility index.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 10/3/2019 due to an increase in the volatility index.
E
Sell
9/18/2019Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 9/18/2019 due to a decline in the volatility index and growth index. Total revenue declined 44.99% from $2.96M to $1.63M, operating cash flow declined 44.83% from -$2.11M to -$3.06M, and EBIT declined 25.93% from -$2.33M to -$2.93M.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 9/18/2019 due to a decline in the volatility index and growth index. Total revenue declined 44.99% from $2.96M to $1.63M, operating cash flow declined 44.83% from -$2.11M to -$3.06M, and EBIT declined 25.93% from -$2.33M to -$2.93M.
D
Sell
4/18/2019Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 4/18/2019 due to an increase in the growth index, volatility index and total return index.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 4/18/2019 due to an increase in the growth index, volatility index and total return index.
E
Sell
4/3/2019Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 4/3/2019 due to a decline in the growth index and efficiency index. Net income declined 942.39% from -$2.35M to -$24.51M, operating cash flow declined 403.95% from -$1.02M to -$5.16M, and earnings per share declined from -$1.7309 to -$3.0627.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 4/3/2019 due to a decline in the growth index and efficiency index. Net income declined 942.39% from -$2.35M to -$24.51M, operating cash flow declined 403.95% from -$1.02M to -$5.16M, and earnings per share declined from -$1.7309 to -$3.0627.
D
Sell
11/14/2018Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 11/14/2018 due to a noticeable increase in the growth index, solvency index and efficiency index. Earnings per share increased from -$10.3457 to -$1.7309, net income increased 74.27% from -$9.14M to -$2.35M, and EBIT increased 25.34% from -$5.44M to -$4.06M.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 11/14/2018 due to a noticeable increase in the growth index, solvency index and efficiency index. Earnings per share increased from -$10.3457 to -$1.7309, net income increased 74.27% from -$9.14M to -$2.35M, and EBIT increased 25.34% from -$5.44M to -$4.06M.
E
Sell
10/8/2018Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 10/8/2018 due to a decline in the volatility index.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 10/8/2018 due to a decline in the volatility index.
D
Sell
9/21/2018Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 9/21/2018 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 109.78% from -$3.56M to $348.1, and EBIT increased 1.24% from -$5.5M to -$5.44M.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 9/21/2018 due to an increase in the volatility index, growth index and total return index. Operating cash flow increased 109.78% from -$3.56M to $348.1, and EBIT increased 1.24% from -$5.5M to -$5.44M.
E
Sell
6/21/2018Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 6/21/2018 due to a decline in the volatility index.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 6/21/2018 due to a decline in the volatility index.
D
Sell
6/6/2018Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 6/6/2018 due to an increase in the volatility index.
Altimmune, Inc. (ALT) was upgraded to D- from E+ on 6/6/2018 due to an increase in the volatility index.
E
Sell
5/17/2018Downgrade
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 5/17/2018 due to a decline in the growth index, volatility index and efficiency index. EBIT declined 217.7% from -$1.73M to -$5.5M, total capital declined 5.64% from $49.33M to $46.54M, and total revenue declined 4.19% from $2.81M to $2.69M.
Altimmune, Inc. (ALT) was downgraded to E+ from D- on 5/17/2018 due to a decline in the growth index, volatility index and efficiency index. EBIT declined 217.7% from -$1.73M to -$5.5M, total capital declined 5.64% from $49.33M to $46.54M, and total revenue declined 4.19% from $2.81M to $2.69M.
D
Sell
2/1/2018Upgraded
Altimmune, Inc. (ALT) was upgraded to D- from E on 2/1/2018 due to an increase in the valuation index.
Altimmune, Inc. (ALT) was upgraded to D- from E on 2/1/2018 due to an increase in the valuation index.
E
Sell
11/1/2017Upgraded
Altimmune, Inc. (ALT) was upgraded to E from E- on 11/1/2017 due to a large increase in the solvency index, growth index and efficiency index. Total revenue increased 914.02% from $299.6 to $3.04M, the quick ratio increased from 0.45 to 2.81, and total capital increased 129.01% from $33.45M to $76.6M.
Altimmune, Inc. (ALT) was upgraded to E from E- on 11/1/2017 due to a large increase in the solvency index, growth index and efficiency index. Total revenue increased 914.02% from $299.6 to $3.04M, the quick ratio increased from 0.45 to 2.81, and total capital increased 129.01% from $33.45M to $76.6M.
E
Sell
7/31/2017None
Altimmune, Inc. (ALT) was downgraded to E- from U on 07/31/2017.
Altimmune, Inc. (ALT) was downgraded to E- from U on 07/31/2017.
NASDAQ
03/18/2025 4:00PM Eastern
Quotes delayed
